Calcium dobesilate
Based on 1 publication(s) in Google Scholar
Calcium dobesilate is a vascular protector with oral activity that can clear hydroxyl free radicals, with an IC50 of 1.1 pM. Calcium dobesilate has antioxidant activity and helps to reduce oxidative stress and inflammation in the retinas of diabetic mice. Calcium dobesilate can be used to study chronic venous diseases, diabetic retinopathy, and the occurrence of hemorrhoids, among other conditions.
Nur für Forschungszwecke. Wir verkaufen nicht an Patienten.
- Reinheit: 98.0%
- CAS. Nr.: 20123-80-2
- Formel: C12H10CaO10S2
- Molecular Weight:418.41
-
Speicherung:
4°C, sealed storage, away from moisture
* In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture)
To place orders, for customer services and technical support, please contact: MedChemExpress USA
Tel: 609-228-6898 E-mail: [email protected] [email protected]
-
Biologische Aktivität
-
Chemical Information
-
Lösungsmittel & Löslichkeit
- Reinheit & Dokumentation
- Verweise
-
Help & FAQs
-
Anti-Infection Compound Library
HY-L002
-
Apoptosis Compound Library
HY-L003
-
FDA-Approved Drug Library
HY-L022
-
Anti-Aging Compound Library
HY-L034
-
Drug Repurposing Compound Library
HY-L035
-
Antioxidant Compound Library
HY-L037
-
Anti-diabetic Compound Library
HY-L040
-
Oxygen Sensing Compound Library
HY-L045
-
Ferroptosis Compound Library
HY-L051
-
Anti-COVID-19 Compound Library
HY-L052
-
NMPA-Approved Drug Library
HY-L053
-
Orally Active Compound Library
HY-L061
-
FDA Approved & Pharmacopeial Drug Library
HY-L066
-
Anti-Parkinson's Disease Compound Library
HY-L085
-
Neurodegenerative Disease-related Compound Library
HY-L086
-
Off-patent Drug Library
HY-L141
-
Cell Death Library
HY-L162
-
Radioprotector Library
HY-L178
-
Bioactive Compound Library Max
HY-L181
-
MCE Bioactive Compound Library
HY-L001V
-
Drug Repurposing Compound Library Plus
HY-L035P
-
FDA-Approved Drug Library Plus
HY-L022P
-
FDA-Approved Drug Library Mini
HY-L022M
-
Bioactive Compound Library
HY-L001
-
Anti-Fibrosis Compound Library
HY-L185
-
Non-Alcoholic Fatty Liver Disease (NAFLD) Compound Library
HY-L199
-
High-Throughput Bioactive Compound Library
HY-L205
Publications Citing Use of MedChemExpress (MCE) Calcium dobesilate
More
Biologische Aktivität
Calcium dobesilate (500 μM) significantly reduces the chemiluminescence of human PMN cells induced by platelet-activating factor (PAF) and decreases lipid peroxidation caused by oxygen free radicals in human red blood cell membranes[1].
Calcium dobesilate (5-10 mM) lowers MDA levels in human red blood cells[1].
Calcium dobesilate (0-10000 μM, for 5 days) at higher concentrations leads to a rapid decrease in live cells and an increase in the percentage of apoptotic cells[2].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Cell Line:PBMC
-
Concentration:0, 1, 10, 100, 1000, 10000 μM
-
Incubation Time:5 days
-
Result:Inhibited cell proliferation.
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Animal Model:Db/db mice[3]
-
Dosage:200 mg/kg; daily; 15 days
-
Administration:Oral
-
Result:Inhibited diabetes-induced increases in NF-κB, IL-6, IL-8, TNF-α, and MCP-1, suppressed IL-1β-induced NF-kβ activation, and reduced TNF-α-induced upregulation of IL-6 and IL-18.
| NCT Number | Sponsor | Condition | Start Date |
Phase
|
|---|---|---|---|---|
| NCT01329991 | Plexxikon| | 2011-05 | PHASE1 |
Chemical Information
-
CAS. Nr. 20123-80-2
-
Appearance Solid
-
Molecular Weight 418.41
-
Formel C12H10CaO10S2
-
Color White to off-white
-
SMILES
O=S(C1=CC(O)=CC=C1O)([O-])=O.O=S(C2=CC(O)=CC=C2O)([O-])=O.[Ca+2]
-
Versand
Room temperature in continental US; may vary elsewhere.
-
Speicherung
4°C, sealed storage, away from moisture
* In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture)
Publications (1)
-
Journal Impact Factor
-
Most Recent
-
Am J Cancer Res
Calcium dobesilate prevents PLD-induced hand-foot syndrome by alleviating capillary endothelial tight junction injury via the HA/CD44 pathway. [Abstract]2023 Jul 15;13(7):3234-3245. PMID: 37559988
Lösungsmittel & Löslichkeit
DMSO : 150 mg/mL (358.50 mM; Need ultrasonic; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)
H2O : ≥ 100 mg/mL (239.00 mM)
* "≥" means soluble, but saturation unknown.
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
* Note: If you choose water as the stock solution, please dilute it to the working solution, then filter and sterilize it with a 0.22 μm filter before use.
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
* Note: If you choose water as the stock solution, please dilute it to the working solution, then filter and sterilize it with a 0.22 μm filter before use.
Konzentration (Stammlösung) × Volumen (Stammlösung) = Konzentration (Ziellösung) × Volumen (Ziellösung)
Select the appropriate dissolution method based on your experimental animal and administration route.
- For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
- To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for In Vivo experiments, it is recommended to prepare freshly and use it on the same day.
- The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.
Add each solvent one by one: 10% DMSO 40% PEG300 5% Tween-80 45% Saline
Solubility: ≥ 2.5 mg/mL (5.98 mM); Clear solution
This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown).
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 400 μL PEG300, and mix evenly; then add 50 μL Tween-80 and mix evenly; then add 450 μL Saline to adjust the volume to 1 mL.
Preparation of Saline: Dissolve 0.9 g sodium chloride in ddH₂O and dilute to 100 mL to obtain a clear Saline solution.
Add each solvent one by one: 10% DMSO 90% (20% SBE-β-CD in Saline)
Solubility: ≥ 2.5 mg/mL (5.98 mM); Clear solution
This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown).
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 900 μL 20% SBE-β-CD in Saline, and mix evenly.
Preparation of 20% SBE-β-CD in Saline (4°C, storage for one week): 2 g SBE-β-CD powder is dissolved in 10 mL Saline, completely dissolve until clear.
Please enter the basic information of animal experiments:
-
-
-
-
Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.
Working solution concentration: 0.22 mg/mL
This product has good water solubility, please refer to the measured solubility data in water/PBS/Saline for details.
Reinheit & Dokumentation
-
Data Sheet (282 KB)
-
SDS (394 KB)
- English - EN (394 KB)
- Français - FR (394 KB)
- Deutsch - DE (394 KB)
- Norwegian - NO (394 KB)
- Español - ES (394 KB)
- Swedish - SV (394 KB)
- Italian - IT (394 KB)
- Korean - KR (394 KB)
- Portuguese - PT (394 KB)
-
Handling Instructions (2659 KB)
Verweise
[1]. J Brunet, et al. In vitro antioxidant properties of calcium dobesilate. Fundam Clin Pharmacol. 1998;12(2):205-12. [Content Brief]
[2]. GA Losa, et al. Prevention of Oxidation and Apoptosis in Human Peripheral Blood Mononuclear Cells Exposed to Calcium Dobesilate. Int J Angiol. 1999;8(5):11-15. [Content Brief]
[3]. Patricia Bogdanov, et al. Calcium dobesilate prevents the oxidative stress and inflammation induced by diabetes in the retina of db/db mice. J Diabetes Complications. 2017 Oct;31(10):1481-1490. [Content Brief]
Complete Stock Solution Preparation Table
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
| Optional Solvent | Concentration Solvent Mass | 1 mg | 5 mg | 10 mg | 25 mg |
|---|---|---|---|---|---|
| H2O / DMSO | 1 mM | 2.3900 mL | 11.9500 mL | 23.9000 mL | 59.7500 mL |
| 5 mM | 0.4780 mL | 2.3900 mL | 4.7800 mL | 11.9500 mL | |
| 10 mM | 0.2390 mL | 1.1950 mL | 2.3900 mL | 5.9750 mL | |
| 15 mM | 0.1593 mL | 0.7967 mL | 1.5933 mL | 3.9833 mL | |
| 20 mM | 0.1195 mL | 0.5975 mL | 1.1950 mL | 2.9875 mL | |
| 25 mM | 0.0956 mL | 0.4780 mL | 0.9560 mL | 2.3900 mL | |
| 30 mM | 0.0797 mL | 0.3983 mL | 0.7967 mL | 1.9917 mL | |
| 40 mM | 0.0598 mL | 0.2988 mL | 0.5975 mL | 1.4938 mL | |
| 50 mM | 0.0478 mL | 0.2390 mL | 0.4780 mL | 1.1950 mL | |
| 60 mM | 0.0398 mL | 0.1992 mL | 0.3983 mL | 0.9958 mL | |
| 80 mM | 0.0299 mL | 0.1494 mL | 0.2988 mL | 0.7469 mL | |
| 100 mM | 0.0239 mL | 0.1195 mL | 0.2390 mL | 0.5975 mL |
* Note: If you choose water as the stock solution, please dilute it to the working solution, then filter and sterilize it with a 0.22 μm filter before use.
Calcium dobesilate Related Classifications
HY-111603 Related Classifications
Powered by Bioz